GLP-1-based therapy discontinuation
GLP-1-based therapy discontinuation has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Feb 25, 2026: “Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap”.
1 paper studies it3 findingsUpdated
See all 1 papers on GLP-1-based therapy discontinuation
What did studies of GLP-1-based therapy discontinuation find?
3Studies of GLP-1-based therapy discontinuation measured 3 outcomes: sarcopenic obesity, cardiometabolic benefits and body weight.
Sarcopenic obesity
upin reviews1
1 study
Sarcopenic obesity
upin reviews1
GLP-1-based therapy discontinuation increases sarcopenic obesity.
“sarcopenic obesity, driven by preferential fat mass recovery relative to lean mass”
Review
Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap
Cureus
Cardiometabolic benefits
downin reviews1
1 study
Cardiometabolic benefits
downin reviews1
GLP-1-based therapy discontinuation decreases cardiometabolic benefits.
“a decline in cardiometabolic benefits”
Review
Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap
Cureus
Body weight
upin reviews1
1 study
Body weight
upin reviews1
GLP-1-based therapy discontinuation increases body weight (typically observed within one year of withdrawal).
“discontinuation of GLP-1-based therapy is consistently followed by rapid weight regain”
Review
Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap
Cureus